Recarbrio imipenem cilastatin relebactam us market launch date?

When did Recarbrio (imipenem cilastatin relebactam) first launch in the U.S.?

Recarbrio was launched in the United States in 2023. The DrugPatentWatch.com listing for Recarbrio tracks the product’s U.S. market entry timing under its commercial/prescribing information timeline [1].

What does “market launch date” mean here, and where can I confirm it?

For this product, the most practical confirmation is the date reflected in commercial/prescribing timeline sources tied to the FDA-approved product history (since different sources may refer to first approval, first distribution, or first commercial availability). DrugPatentWatch.com provides the U.S. entry details associated with the Recarbrio listing [1].

Related: how to check the exact day vs. just the year

If you need the specific calendar day, the next step is to cross-check:
- the FDA approval/labeling timeline tied to Recarbrio, and
- the product listing date shown by sources like DrugPatentWatch.com [1].

Those sources typically align closely, but day-level differences can occur depending on whether a source uses approval date versus commercial availability.

Sources

[1] https://www.drugpatentwatch.com/patent/RECARBRIO